Systemic Therapy for Metastatic Renal-Cell Carcinoma

Choueiri et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d8d0f617a1cc0598d189f7 — DOI: https://doi.org/10.1056/nejmra1601333

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Prospective Multicenter Phase II Study of Gemcitabine Plus Platinum Salt for Metastatic Collecting Duct Carcinoma: Results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) Study· 2007 · 201 citations
2. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma· 2011 · 1,280 citations
3. Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma· 2012 · 458 citations
4. Contemporary Trends in the Utilization of Radiotherapy in Patients With Renal Cell Carcinoma· 2015 · 11 citations
5. A New Protocol for the Followup of Renal Cell Carcinoma Based on Pathological Stage· 1995 · 241 citations